Keywords: F-Star, Merck Serono, Merck KGaA, Targeted biologics, Inflammatory disease

F-Star and Merck Serono in up to 492 million-euro collaboration on novel targeted biologics

Article | 09 September 2011

Print This

Austrian biotech firm F-Star GmbH has entered into a research, license and commercialization agreement with Merck Serono, a division of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in